|Onconova Therapeutics, Inc.|
375 Pheasant Run
United States - Map
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The companys clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates that target kinases, cellular metabolism, or cell division in preclinical development. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.
|Dr. Ramesh Kumar Ph.D.,
Co-Founder, Chief Exec. Officer, Pres and Director
|Dr. E. Premkumar Reddy Ph.D.,
Founder, Lead Scientific Advisor and Director
|Dr. Manoj Maniar Ph.D.,
Sr. VP of Product Devel.
|Dr. Thomas J. McKearn M.D., Ph.D.,
Pres of R&D
|Mr. Ajay Bansal ,
Chief Financial Officer and Sec.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|